chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was exposed to COVID in her home via her daughter from out of state. 07/11 she began experiencing nausea, vomiting, and diarrhea, as well as loss of taste and smell. She presented to the ED with these symptoms and fatigue. She was diagnosed with COVID pneumonia and dehydration and admitted to the COVID Unit.   Problem list: -Severe Covid pneumonia with pulmonary infiltrates and new hypoxia. Symptom onset 7/11/2021 -Hypoxic respiratory failure secondary to above -mildly elevated troponin w/o chest pain -Nausea/vomiting/diarrhea, suspected to be secondary to coronavirus -Acute kidney insufficiency, suspect prerenal azotemia from volume depletion -History of hypertension, currently hypotensive -Weakness -new dx of DMII with steroid induced hyperglycemia     Plan: -Continue inpatient level of care in the Covid unit -Dexamethasone (7/18/2021-) and completed remdesivir (7/17/2021-7/21), supplementary oxygen, Mucinex, albuterol, proning, is at the spirometry. CRP elevated at 19, D-dimer elevated at 1200 will trend CRP but currently not severely hypoxic enough to qualify for Tocilizumab. Troponin downtrended. TTE with right sided heart dyfxn, likely at least partially chronic as CTA does not show any evidence of pulmonary embolus. Would recommend repeat transthoracic echocardiogram after recovery from acute illness and consideration of right heart catheterization if right ventricle dysfunction appears to be persistent. -Sliding scale of insulin started given her history of borderline diabetes with the expectation of hyperglycemia on dexamethasone. 7.5. Continue lantus, medium dose SSI -Resume amlodipine. Continue holding ACE inhibitor given acute kidney insufficiency -Renal function improving, appreciate assistance -PT/OT consulted and rec  -Acetaminophen and Zofran for symptomatic management
Vaccine administered to 17 1/2 years old; A spontaneous report was received from a pharmacist concerning a 17-year old, female patient, who received Moderna's COVID-19 Vaccine (mRNA-1273) and vaccine administered to 17 1/2 years old.  The patient's medical history was not provided. No relevant concomitant medications were reported.   On an unknown date, prior to the onset of the event, the patient received a dose of mRNA-1273 (lot number 041L20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection.  On an unknown date, the 17 1/2-year-old patient verbally stated that she was of 20-years-old. Hence, she was administered with first dose of Moderna vaccine. No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not reported.  The event, vaccine administered to 17 1/2 years old, was considered to be resolved on an unknown date.; Reporter's Comments: This report refers to a case of Product administered to patient of inappropriate age for COVID-19 vaccine , mRNA-1273, lot # 041L20A. There were no reported AEs associated with this case of Product administered to patient of inappropriate age .
Her right knee hurt as much as her left knee did; sick to her stomach; Has had stabbing pain in her legs/painful; weak; A goose egg at the injection site; verbally whelped due to the needle that has the cover; it's bright red; under her left armpit hurts; very tired; Body aches/left arm soreness; cold chills; This spontaneous case was reported by an other health care professional and describes the occurrence of ABDOMINAL DISCOMFORT (sick to her stomach), PAIN (Has had stabbing pain in her legs/painful), ASTHENIA (weak), VACCINATION SITE MASS (A goose egg at the injection site) and VACCINATION SITE PAIN (verbally whelped due to the needle that has the cover) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 067F21A, 030A21A and 09K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Knee replacement (replaced 8 weeks ago) and Lymph node excision (removed in the past). Previously administered products included for Product used for unknown indication: flu vaccine (from a flu shot 10 years ago). Past adverse reactions to the above products included Guillain-Barre syndrome with flu vaccine.   On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In November 2021, the patient experienced ABDOMINAL DISCOMFORT (sick to her stomach), ASTHENIA (weak), VACCINATION SITE MASS (A goose egg at the injection site), VACCINATION SITE PAIN (verbally whelped due to the needle that has the cover), VACCINATION SITE ERYTHEMA (it's bright red), AXILLARY PAIN (under her left armpit hurts), FATIGUE (very tired), MYALGIA (Body aches/left arm soreness) and CHILLS (cold chills). November 2021, the patient experienced PAIN (Has had stabbing pain in her legs/painful). On 16-Nov-2021, the patient experienced ARTHRALGIA (Her right knee hurt as much as her left knee did). At the time of the report, ABDOMINAL DISCOMFORT (sick to her stomach), PAIN (Has had stabbing pain in her legs/painful), ASTHENIA (weak), VACCINATION SITE PAIN (verbally whelped due to the needle that has the cover), VACCINATION SITE ERYTHEMA (it's bright red), AXILLARY PAIN (under her left armpit hurts), FATIGUE (very tired), MYALGIA (Body aches/left arm soreness), CHILLS (cold chills) and ARTHRALGIA (Her right knee hurt as much as her left knee did) outcome was unknown and VACCINATION SITE MASS (A goose egg at the injection site) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported. Treatment details were not provided.   This case was linked to MOD-2021-390449, MOD-2021-390455 (Patient Link).
hot injection site; hard injection site; Vaccination site pruritus; Vaccination site rash; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE WARMTH (hot injection site), VACCINATION SITE INDURATION (hard injection site), VACCINATION SITE PRURITUS (Vaccination site pruritus) and VACCINATION SITE RASH (Vaccination site rash) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension.    On 28-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Jan-2021, the patient experienced VACCINATION SITE WARMTH (hot injection site), VACCINATION SITE INDURATION (hard injection site), VACCINATION SITE PRURITUS (Vaccination site pruritus) and VACCINATION SITE RASH (Vaccination site rash). The patient was treated with PARACETAMOL (TYLENOL) for Inflammation, at a dose of 1 dosage form and IBUPROFEN for Inflammation, at a dose of 1 dosage form. At the time of the report, VACCINATION SITE WARMTH (hot injection site), VACCINATION SITE INDURATION (hard injection site), VACCINATION SITE PRURITUS (Vaccination site pruritus) and VACCINATION SITE RASH (Vaccination site rash) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications include a blood pressure medication and statin.   Treatment includes a topical anti-histamine for itching.   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Non-significant follow up updated on 06-Jul-2021: updated contact information.
In error: Administered 0.1 ml Td ID instead of PPD. Left forearm with 10 mm area of induration. No erythema or itch or pain. 8/26/04: Right groin with 20 x020 mm Lymphoid development.
Hemifacial Spasms left side started on 4/12 and continued 48 hours until I took a muscle relaxer. Never occurred prior to vaccine
Patient received flu shot in right deltoid at 12:10 PM. He returned at 3:00 PM with his right arm shaking at rest. He had no injection site symptoms, no arm soreness, and still had full range of motion. However, whenever he stopped moving his arm and it was at rest it was trembling uncontrollably. The patient was instructed to wait 24 hours and if no improvement, go see a doctor to be evaluated.
This spontaneous report was received from a medical assistant and refers to 2 patients of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 27-SEP-2016, the patient was vaccinated with an improperly stored dose of VARIVAX 0.5 ml, subcutaneously, lot # M023379 with an expiration date: 11-MAY-2018. Administered dose of VARIVAX experienced temperature excursion of 11.1 Celsius degree for 1 hour 40 minutes, on an unknown date. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Hair falling out in clumps upon washing, combing, and putting in a pony tail.
I tested positive for Covid; I tested positive for Covid; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 26Jan2021 as dose1, single (Lot number: EL9261), in right arm, on 15Feb2021 as dose2, single (Lot number: EL3246), in left arm and on 28Sep2021 as dose 3 (booster), single (Lot number: 30158BA) at the age of 71 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing), notes: High blood pressure treated with medication. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "I tested positive for Covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (04May2022) Positive; (11May2022) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Adverse event: Consumer tested positive for Covid on 04May2022. Consumer began Paxlovid on May 05May2022. Her primary symptoms were extreme fatigue, chills, a slight cough, and some nasal drainage. By 09May2022 she was symptom free and tested negative on 11May2022. On 15May2022, she developed nasal stuffiness which she thought might be a new allergy to pollen. She spoke with the Pharmacist on May 18, 2022 about her nasal stuffiness. She did not feel it was an allergy because she did not have any other allergy symptoms. She advised me to take Mucinex which she did. We were to visit her son and his family to help with the new baby this coming 22May2022. Yesterday she decided to take a Covid test, never dreaming it would be positive. She called her primary care physician and he advised her not to go because of the newborn. This morning she was researching rebound cases of Covid after taking Paxlovid and found that this can occur. She was hoping her information can further the Knowledge of a virus that was constantly mutating.
This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of ABORTION SPONTANEOUS (lost the pregnancy) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced ABORTION SPONTANEOUS (lost the pregnancy) (seriousness criterion medically significant), EXPOSURE DURING PREGNANCY (Vaccine exposure during Pregnancy) and PRODUCT DOSE OMISSION ISSUE (Missed second dose). At the time of the report, ABORTION SPONTANEOUS (lost the pregnancy) outcome was unknown and EXPOSURE DURING PREGNANCY (Vaccine exposure during Pregnancy) and PRODUCT DOSE OMISSION ISSUE (Missed second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.   No treatment information was provided.  Moderna Customer Care agent attempted a warm transfer but when retrieving the caller the caller was no longer on the line. But the agent informed that  the caller received the first dose of the Moderna COVID-19 vaccine in March. At  the time of vaccination the caller did not know they were pregnant and did not get second dose once they found out for safety reasons. The caller lost the pregnancy and now wants to know if they can get the second dose.  This is a case of product exposure during pregnancy with associated AEs for this female patient of unknown age. Patient declined further contact no further details is expected.; Sender's Comments: This is a case of product exposure during pregnancy with associated AEs for this female patient of unknown age. Patient declined further contact no further details is expected.
Patient had worsening SOB (started around 09/04) which he expressed on 09/08 when he came in for chemotherapy. Patient has received 3rd dose of COVID-19 vaccine on 09/02, but is also receiving chemotherapy regimen which has a black box warning for VTE. Heme/onc decided to admit patient where CTA was done and patient was positive for PE. Heparin gtt was initiated with admission on 09/08 and continued to discharge on 09/10 when patient was switched to Eliquis. Patient reported no other signs and symptoms besides SOB throughout his stay.
pt recv vax 29JAN96 & 24hr p/vax pt exp upper resp flu-like sx;pt has recovered;
This spontaneous case was reported by a consumer and describes the occurrence of RASH (Patient has a rash after getting the Moderna covid shot) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jan-2021, the patient experienced RASH (Patient has a rash after getting the Moderna covid shot). At the time of the report, RASH (Patient has a rash after getting the Moderna covid shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Muscle pain; Mobility decreased; chills; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Muscle pain), MOBILITY DECREASED (Mobility decreased), CHILLS ( chills) and DIARRHOEA (Diarrhea) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, the patient experienced DIARRHOEA (Diarrhea). On an unknown date, the patient experienced MYALGIA (Muscle pain), MOBILITY DECREASED (Mobility decreased) and CHILLS ( chills). At the time of the report, MYALGIA (Muscle pain), MOBILITY DECREASED (Mobility decreased) and CHILLS ( chills) had resolved and DIARRHOEA (Diarrhea) outcome was unknown. Not Provided          No treatment information was provided. This case was linked to MOD-2021-046493 (E2B Linked Report). Reporter did not allow further contact no concomitant drugs included   This case was linked to MOD-2021-046493 (E2B Linked Report).; Sender's Comments:  MOD-2021-046493:Cross linked case for first dose
Started to have horrible body aches and chills about 10 hours after shot. Felt very febrile with frozen finger tips. Could not warm them up. Continued fatigue and febrile and malaise.
Information has been received from a physician's assistant concerning a 21 year old female patient who on 19-JUL-2007 was vaccinated with a 0.5 mL dose of GARDASIL.  On 13-JUN-2008 the patient was diagnosed with rheumatoid arthritis.  It was unknown if the patient sought medical attention.  Therapy with GARDASIL was discontinued.  At the time of the report, the patient had not recovered from this event.  Follow-up information has been received from a nurse concerning a patient with seasonal allergies, no known drug allergy, no history of an infectious process before the start of the rheumatoid arthritis symptoms and no family history of any autoimmune disorder.  Concomitant therapy included ALLEGRA.  There were no other vaccines given at that time.  The patient presented to the office on 22-MAY-2008 with swollen knuckles.  The rheumatoid arthritis diagnostics panel was drawn that day results:  C-Reaction Protein 11.2; Erythrocyte Sedimentation Rate (sed rate) 32,; uric acid was normal.  On 21-JUL-2008 the sed rate was normal at 7, but the sed rate was back up to 33 in October 2008.  The patient was treated with methotrexate and prednisone.  It was stated that there was no serious criteria.  At the time of the report, the patient's outcome was unknown.  Follow-up information has been received from the physician's assistant concerning the 21 year female patient with no pre-existing allergies (previously reported with seasonal allergies) and no illness at time of vaccination.  The patient was vaccinated with the first dose of GARDASIL at 12:20 pm on 19-JUL-2007.  In July 2007 (previously reported as 13-JUN-2008) the patient experienced joint pain, swelling and stiffness.  On 27-JUN-2008, the patient was diagnosed with rheumatoid arthritis.  The patient's sed rate showed 34.  The interleukin-6 result was 11.3.  The patient's CCP exceeded 250.  The serum electrophoresis showed polyclonal hyper gamma global erema.  Additional information has been requested.
Roughly 9 hrs after shot malaise. During next 30 hours loss of balance, incontinence, nausea, mild headache. By 40 hours symptoms had diminished and I could eat, although sparingly, again
chills, flu like symptoms, joint pain, tiredness, headache,injection site swelling,injection site redness, feeling unwell, muscle pain
This case was reported by a pharmacist via call center representative and described the occurrence of injection site pain in a 77-year-old male patient who received SHINGRIX (batch number B9739, expiry date 22nd November 2020) for prophylaxis. On 13th August 2018, the patient received the 2nd dose of SHINGRIX (intramuscular) .5 ml. In August 2018, less than a week after receiving SHINGRIX, the patient experienced injection site pain and shivering. The patient was treated with ibuprofen and fenoprofen. On an unknown date, the outcome of the injection site pain and shivering were unknown.  It was unknown if the reporter considered the injection site pain and shivering to be related to SHINGRIX. Additional details were reported as follows: The patient received SHINGRIX vaccine in right arm. The patient rated pain as 9 from a scale of 1-10 and 10 being the worst. No further details were provided.
Onset of constant tremors and seisures that to date have been unrelenting and non responsive to medication and treatment.  Currently at hospital.
he also had COVID-19/tested positive for Covid-19; he also had COVID-19/tested positive for Covid-19; This is a spontaneous report received from a contactable consumer (patient). A 43-years-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Patient received the first dose of the Pfizer-BioNTech COVID-19 Vaccine but he also had COVID-19 and didn't know it. The day that he got his shot, that night he was really sick. He said he felt really ill and had a loss of taste. He saw a doctor, and it was determined that he tested positive for COVID-19. He stated that he more than likely already had it but didn't find out till after he'd already gotten the shot and was sick. Outcome of the events was unknown.  Information on the lot/batch number has been requested.
Red, hot, swollen and a hard lump at  injection sites 3 to 4 inches in diameter in  left arm. Same on right arm but 5 inches  in diameter.
he patient presents with 58-YEAR-OLD FEMALE HISTORY OF CHRONIC ALCOHOLISM, MELANOMA PRESENTS TO EMERGENCY DEPARTMENT WITH MULTIPLE COMPLAINTS.  STATES APPROXIMATELY 5 MONTHS AGO SHE RECEIVED HER JOHNSON & JOHNSON CORONAVIRUS VACCINE AND SINCE THAT TIME HAS FELT FATIGUED WITH LITTLE ENERGY.  STATES SHE ALSO HAS UNEXPECTED WEIGHT LOSS OF ABOUT 20 LB SINCE THIS YEAR.  SHE SAW A DOCTOR AT THE CLINIC THIS MORNING WHO REFERRED HER TO THE EMERGENCY DEPARTMENT.  STATES SHE DRINKS VODKA DAILY AND HAS BEEN CUTTING BACK TO 2 SERVINGS PER DAY.  STATES SHE HAS TINGLING IN HER BILATERAL HANDS AND FEET AND FEELS NAUSEATED.  NOTED TO BE TACHYCARDIC UPON ARRIVAL.  HER DOCTOR SENT HER WITH A LETTER RECOMMENDING INPATIENT ALCOHOL DETOX.  SHE DENIES ANY CHEST PAIN OR SHORTNESS OF BREATH, NO NECK PAIN OR STIFFNESS.  NO AUDITORY VISUAL HALLUCINATIONS.  NO BLACK OR BLOODY STOOLS.  NO HEMATEMESIS OR ABDOMINAL PAIN..  The onset was chronic.  The course/duration of symptoms is fluctuating in intensity.  Location: SEE HPI. The character of symptoms is SEE HPI.  The degree at onset was moderate.  The degree at present is moderate.  Risk factors consist of SEE HPI.  Therapy today: see nurses notes.  Associated symptoms: denies chest pain, denies headache and denies back pain.  .
Patient's wife came into the pharmacy on 11/20/23 between 2:30-3:00pm and stated that her husband received the covid vaccine on 10/27/23. The next morning 10/28/23 blisters started forming on his hands and feet. They went to the clinic then to the hospital to receive treatment. Patient died on 10/31/23.
Information has been received from a registered nurse concerning a white male who on 07-JUL-1997 was vaccinated with a dose of Varivax. Subsequently, the patient developed a generalized rash of 50-200 lesions. The patient was not hospitalized. Vaccine failure was noted. This was MD documented/evaluated. Follow-up information indicated that there was no further information. No additional information is expected.
toes are all red; toes are on fire; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (toes are all red) and BURNING SENSATION (toes are on fire) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (toes are all red) and BURNING SENSATION (toes are on fire). At the time of the report, ERYTHEMA (toes are all red) and BURNING SENSATION (toes are on fire) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Non-significant follow-up received, No new information
After giving the vaccine I realized that I gave it wrong.  I did not know that the vials were not diluted already.  I thought that the amount in the vial was what was left in the vial from previous doses.  I didn't see posted anywhere how to give this vaccine.  Since I know most vaccines are 0.5 ml that's what I assumed.  All the other medical assistants and nurses were busy so I didn't have anyone to ask.  I normally do not work at this location and any other time I've given covid vaccines they were done at other locations, with instructions on drawing up and administering.